ZD 8321

Drug Profile

ZD 8321

Latest Information Update: 15 Sep 2000

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antiasthmatics
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute lung injury; Adult respiratory distress syndrome; Bronchitis; Chronic obstructive pulmonary disease; Heart failure; Systemic inflammatory response syndrome

Most Recent Events

  • 15 Sep 2000 Discontinued-Unspecified Phase in Chronic obstructive pulmonary disease in USA (PO)
  • 15 Sep 2000 Discontinued-Phase I in Systemic inflammatory response syndrome in USA (PO)
  • 15 Sep 2000 Discontinued-II for Acute lung injury in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top